CABOMETYX® - for Renal Cancer
CABOMETYX® (Cabozantinib) - for Advanced Renal Cancer
Monitor closely for nausea, vomiting, diarrhea and palmar-plantar erythrodysesthesia syndrome. Treatment continued until disease progression or unacceptable toxicity
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
CABOMETYX® (Cabozantinib) PO 60 mg Daily until Disease Progression N/A N/A N/A N/A